Patients with macular pathology benefit from EDOF IOLs, study shows
Implantation of extended depth of focus (EDOF) intraocular lenses (IOLs) in patients with mild macular pathology is both safe and effective, according to a poster presented at the 42nd Congress of the ESCRS.
This retrospective case series included 22 eyes from 15 patients, all of whom had cataract surgery. They were implanted with either a nondiffractive wavefront-shaping EDOF IOL (AcrySof IQ Vivity) or a refractive aspheric hybrid EDOF IOL (LUCIDIS) over 2.5 years.
The study evaluated several key factors, including corrected distance visual acuity (CDVA), distance-corrected near visual acuity, defocus curve, contrast sensitivity, central foveal thickness, and quality of life. It found that the average CDVA improved from 0.45 before surgery to 0.20 after surgery. Most patients achieved a CDVA equivalent to Snellen 6/6–6/12, and their contrast sensitivity remained normal. Although there was a slight reduction in contrast sensitivity, 90% of patients experienced a significant improvement in their quality of life and reported minimal visual impairment according to the VF-14 questionnaire.
Overall, the study concludes that EDOF IOL implantation is a safe and effective option for patients with mild macular pathology, leading to high patient satisfaction and improved visual outcomes.
Reference
Hanna R, et al. Extended depth-of-focus intraocular lens implantation in eyes with retinal pathology. Poster presented at: 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS); September 6-10, 2024; Barcelona, Spain.
